REIMBURSEMENT UNRAVELLED: EU challenges of drug/device combinations
23 January 2015. Manufacturers of drug/device combination products need to consider carefully their reimbursement position and be prepared to collect the data necessary to support reimbursement submissions. Where a price premium is sought compared to current products then the data requirements are likely to be significant. Dr Mark Charny examines how to model your reimbursement approach to a variety of countries around Europe.